Table 1 Baseline characteristics of participants according to the tertiles of AGR (n = 196). Values are mean ± SD or n (%)

No. of participants

196

65

64

67

Age, years

60.44 ± 10.14

62.78 ± 9.55

61.86 ± 9.31

56.82 ± 10.56

0.001

Male

126 (64.29%)

45 (69.23%)

37 (57.81%)

44 (65.67%)

0.384

Never smoker

127 (64.80%)

38 (58.46%)

45 (70.31%)

44 (65.67%)

0.364

Hypertension

66 (33.67%)

22 (33.85%)

25 (39.06%)

19 (28.36%)

0.432

Leukocyte, 10⁹/L

7.07 ± 2.57

7.70 ± 2.79

7.05 ± 2.17

6.48 ± 2.60

0.023

Neutrophil, 10⁹/L

4.97 ± 2.21

5.35 ± 2.40

4.99 ± 1.91

4.58 ± 2.24

0.132

Lymphocyte, 10⁹/L

1.31 ± 0.55

1.42 ± 0.56

1.33 ± 0.55

1.19 ± 0.54

0.055

Platelets, 10⁹/L

256.67 ± 98.46

292.65 ± 109.65

258.56 ± 98.37

219.97 ± 71.43

< 0.001

Albumin, g/L

41.84 ± 4.65

38.15 ± 4.66

43.37 ± 3.56

43.98 ± 3.23

< 0.001

Globulin, g/L

28.51 ± 4.97

33.18 ± 3.84

28.97 ± 2.56

23.52 ± 2.33

< 0.001

ALK rearrangement

0.395

No

136 (69.39%)

41 (63.08%)

45 (70.31%)

50 (74.63%)

Yes

3 (1.53%)

1 (1.54%)

2 (3.12%)

0 (0.00%)

Unknown

57 (29.08%)

23 (35.38%)

17 (26.56%)

17 (25.37%)

EGFR mutation

0.200

No

83 (42.35%)

27 (41.54%)

31 (48.44%)

25 (37.31%)

Yes

57 (29.08%)

15 (23.08%)

16 (25.00%)

26 (38.81%)

Unknown

56 (28.57%)

23 (35.38%)

17 (26.56%)

16 (23.88%)

Histology

0.033

Adenocarcinoma

124 (63.27%)

49 (75.38%)

42 (65.62%)

33 (49.25%)

Squamous cell carcinoma

47 (23.98%)

9 (13.85%)

15 (23.44%)

23 (34.33%)

Others

25 (12.76%)

7 (10.77%)

7 (10.94%)

11 (16.42%)

Tumor stage

0.853

III

30 (15.31%)

11 (16.92%)

10 (15.62%)

9 (13.43%)

IV

166 (84.69%)

54 (83.08%)

54 (84.38%)

58 (86.57%)

ECOG PS score

0.348

0

136 (69.39%)

41 (63.08%)

45 (70.31%)

50 (74.63%)

1

60 (30.61%)

24 (36.92%)

19 (29.69%)

17 (25.37%)

Number of metastases

0.955

< 3

153 (78.06%)

50 (76.92%)

50 (78.12%)

53 (79.10%)

≥ 3

43 (21.94%)

15 (23.08%)

14 (21.88%)

14 (20.90%)

Number of previous treatment lines

0.070

< 3

107 (54.59%)

40 (61.54%)

38 (59.38%)

29 (43.28%)

≥ 3

89 (45.41%)

25 (38.46%)

26 (40.62%)

38 (56.72%)

Number of previous chemotherapy lines

0.029

≤ 2

153 (78.06%)

54 (83.08%)

54 (84.38%)

45 (67.16%)

> 2

43 (21.94%)

11 (16.92%)

10 (15.62%)

22 (32.84%)

Previous targeted therapy

69 (35.20%)

21 (32.31%)

19 (29.69%)

29 (43.28%)

0.222

Previous radiotherapy

35 (17.86%)

12 (18.46%)

9 (14.06%)

14 (20.90%)

0.587

Previous immunotherapy

32 (16.33%)

11 (16.92%)

10 (15.62%)

11 (16.42%)

0.980

Anlotinib monotherapy

156 (79.59%)

53 (81.54%)

52 (81.25%)

51 (76.12%)

0.685